Clinical Trial Update: Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

View source ↗

Summary

An open-label, multicenter real-world study of durvalumab (Imfinzi) is completed, assessing its use in patients with lung cancer and biliary tract cancer. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer, Biliary Tract Cancer | Status: COMPLETED